Interviews

















































Interviews in Dallas are for the West and the South regions. Offers being extended the week of the ADCOM. Options will be solid and pay is 120-140k with bonus around 50k at plan. Stock options 10k-15k. Car allowance of $800. AVEO wants/needs the best to sell tivo in a tough market. Product will get approved.
 






I always like it when someone knows for sure a drug will be approved. Usually means it won't! But let's say it does then what? About 24 months of hell. Why? If your in oncology you know why. If the product was 5 times better no problem. But its what big pharma calls a me to product. Does not offer anything better then what's on the market. Then you will be working for people who have no true experience in oncology much less launching a new product in this market. Is it really worth taking a risk?
 






Interviews in Dallas are for the West and the South regions. Offers being extended the week of the ADCOM. Options will be solid and pay is 120-140k with bonus around 50k at plan. Stock options 10k-15k. Car allowance of $800. AVEO wants/needs the best to sell tivo in a tough market. Product will get approved.


Stock and bonus are off a bit. Base is accurate. They may go higher on base for the right person. Bonus at plan is $40K and the options for reps are more in the 2K range. I went very far along in the process before walking away.

In terms of getting approval…my guess is they will get approved but as another poster pointed out nothing is guaranteed. Appears to be safe and effective, and that is really the only threshold for cancer drugs. Once in the market Nexavar is the least of their worries. Doubtful they will take much first line business away from Sutent…just ask GSK with Votrient what that looks and feels like. Doubtful little ol’ Aveo and Astellas are going to do any better than GSK did with questionable data at best ion TIVO-1. Affinitor has the lock on second line so I believe this drug is going to have a really tough go of it.

Tough part is we all know that Genentech does the heavy lifting on Tarceva and Medivation on Xtandi, so it is unclear what impact Astellas has in the oncology community…we know that Aveo has little impact and it’s highly unlikely the best reps with the best access will jump to Aveo.

If you need a job take it, if you are in big pharma oncology take it. Other than that I can't see this being a promising move.
 






Thank you for this valuable info. How many interviews did you have? Were you offered the job? Is the offer contingent on positive ADCOM? What about what the other poster said about cars? Is it allowance? Thank you for any additional info. Big Pharma Oncology here and feeling micromanaged and needing change.
 












Stock and bonus are off a bit. Base is accurate. They may go higher on base for the right person. Bonus at plan is $40K and the options for reps are more in the 2K range. I went very far along in the process before walking away.

In terms of getting approval…my guess is they will get approved but as another poster pointed out nothing is guaranteed. Appears to be safe and effective, and that is really the only threshold for cancer drugs. Once in the market Nexavar is the least of their worries. Doubtful they will take much first line business away from Sutent…just ask GSK with Votrient what that looks and feels like. Doubtful little ol’ Aveo and Astellas are going to do any better than GSK did with questionable data at best ion TIVO-1. Affinitor has the lock on second line so I believe this drug is going to have a really tough go of it.

Tough part is we all know that Genentech does the heavy lifting on Tarceva and Medivation on Xtandi, so it is unclear what impact Astellas has in the oncology community…we know that Aveo has little impact and it’s highly unlikely the best reps with the best access will jump to Aveo.

If you need a job take it, if you are in big pharma oncology take it. Other than that I can't see this being a promising move.


You say you went far in the process... Can you elaborate on the process? I heard all the interview were completed in one day so did you just walk away half way through the day? Sounds strange to me.
 












Thank you for this valuable info. How many interviews did you have? Were you offered the job? Is the offer contingent on positive ADCOM? What about what the other poster said about cars? Is it allowance? Thank you for any additional info. Big Pharma Oncology here and feeling micromanaged and needing change.

No car allowance-company cars - Volvo's, they were asking AD's and managers to join prior to ODAC, reps upon ODAC vote-depending on outcome. VP of Sales is a Pfizer guy so take that for what it's worth in terms of whether there will be micromanagement at Aveo.
 






All of this information is pretty contradictory. I guess that's why I should know better than to look at Cafe Pharma! I would think a car allowance is more likely with a start up. Also, everyone I know that has gone to a startup has been given thousands of stock options upon hire.

I heard Astellas was offering a sign on bonus plus severance if not approved. I would feel better waiting to start upon fda approval rather than take a risk like this.
 






All of this information is pretty contradictory. I guess that's why I should know better than to look at Cafe Pharma! I would think a car allowance is more likely with a start up. Also, everyone I know that has gone to a startup has been given thousands of stock options upon hire.

I heard Astellas was offering a sign on bonus plus severance if not approved. I would feel better waiting to start upon fda approval rather than take a risk like this.

Call the Bowden Group who is the recruiter for Aveo. Volvo is spot on. You'll get thousands of options 2 to 3 thousand. For reps your offer will be contingent on approval.
 












Stock and bonus are off a bit. Base is accurate. They may go higher on base for the right person. Bonus at plan is $40K and the options for reps are more in the 2K range. I went very far along in the process before walking away.

In terms of getting approval…my guess is they will get approved but as another poster pointed out nothing is guaranteed. Appears to be safe and effective, and that is really the only threshold for cancer drugs. Once in the market Nexavar is the least of their worries. Doubtful they will take much first line business away from Sutent…just ask GSK with Votrient what that looks and feels like. Doubtful little ol’ Aveo and Astellas are going to do any better than GSK did with questionable data at best ion TIVO-1. Affinitor has the lock on second line so I believe this drug is going to have a really tough go of it.

Tough part is we all know that Genentech does the heavy lifting on Tarceva and Medivation on Xtandi, so it is unclear what impact Astellas has in the oncology community…we know that Aveo has little impact and it’s highly unlikely the best reps with the best access will jump to Aveo.

If you need a job take it, if you are in big pharma oncology take it. Other than that I can't see this being a promising move.

GNE and Medivation do the heavy lifting on Tar and Xt? Are you kidding me? Please dont make comments that have no basis in reality. You come off looking silly